Literature DB >> 18729010

Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.

Iain C Macdougall1.   

Abstract

Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729010

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  2 in total

1.  Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Authors:  Jennifer M Green; Karen Leu; Angela Worth; Richard B Mortensen; David K Martinez; Peter J Schatz; Don M Wojchowski; Peter R Young
Journal:  Exp Hematol       Date:  2012-03-06       Impact factor: 3.084

Review 2.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

Authors:  Kathlynn C Brown
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.